-
Elucidating the Function and Downstream Targets of LRRK2
… into neurons, cultured primary neurons and brains from LRRK2 BAC transgenic mice will be used. under normal … and ‘stressed’ conditions. The most compelling substrate from these studies will be studied in vivo using LRRK2 BAC …
-
Mifunctional Cembranoids for Therapy of Parkinson’s Disease
… Final Outcome Beta-cembrane (4R) is one extract from tobacco plants, and it has been found that 4R has a … improved 6-OHDA-induced symptoms and protected neurons from death in a PD model. The possible mechanisms of 4R …
-
Assessing the Therapeutic Potential of iDA Neuronal Cells in Autologous Strategy
… a pre-clinical model of PD. iDAN cells will be generated from the same diseased pre-clinical models and then … Project Description: Skin fibroblasts will be biopsied from pre-clinical models treated unilaterally with 6-OHDA to …
-
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
… PD progresses, contributing to a gradually briefer benefit from each dose of the drug. The new idea we aim to test is … We will also check levodopa blood levels during the scan. From these data, we will calculate ke in the midbrain and in …
-
Developing Disease-modifying Chemical Probes to Inhibit Alpha-synuclein Accumulation
… This grant builds upon the research from a prior grant: Disease-modifying Chemical Probes to … Aggregation Promising Outcomes of Original Grant: Funding from The Michael J. Fox Foundation (MJFF) has facilitated …
-
Developing a Blocker of Alpha-synuclein Production for the Treatment of Parkinson's Disease
… translation, a step in the process of protein production from the DNA template. Our most promising therapeutic … through the body and whether it can pass into the brain from the blood. Our goal is to compare Syn-516 or a similar …